RPRX · Royalty Pharma plc

$58.83 -0.19 (-0.32%) At close · Jul 24

Market Cap

$33.88B

575.83M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Terrance Coyne	CFO	$1,323,000	—	—	—	—	—	$1,323,000
Christopher Hite	Chairman	$1,323,000	—	—	—	—	—	$1,323,000
Marshall Urist	SVP, Research and Investments	$1,323,000	—	—	—	—	—	$1,323,000
George Lloyd	Senior Advisor; former Executive Vice President, Investments & Chief Legal Officer	$1,323,000	—	—	—	—	—	$1,323,000
Pablo Legorreta	CEO	$937,500	—	—	—	—	—	$937,500

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Christopher Hite	Chairman	$1,260,000	—	—	—	—	—	$1,260,000
Marshall Urist	SVP, Research and Investments	$1,260,000	—	—	—	—	—	$1,260,000
Terrance Coyne	CFO	$1,260,000	—	—	—	—	—	$1,260,000
George Lloyd	Senior Advisor; former Executive Vice President, Investments & Chief Legal Officer	$1,260,000	—	—	—	—	—	$1,260,000

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Christopher Hite	Chairman	$1,200,000	$3,360,000	—	—	—	—	$4,560,000
George Lloyd	Senior Advisor; former Executive Vice President, Investments & Chief Legal Officer	$1,200,000	$3,360,000	—	—	—	—	$4,560,000
Marshall Urist	SVP, Research and Investments	$1,200,000	$3,360,000	—	—	—	—	$4,560,000
Terrance Coyne	CFO	$1,200,000	$3,360,000	—	—	—	—	$4,560,000

Key facts CIK 1802768 CUSIP G7709Q104 13F (30d) 111 filings 111 filers Visit website Investor relations